Furthermore, the data from WB, qRT-PCR, and immunofluorescence assays revealed that FADD expression was inhibited in TMZ-resistant glioma cells by ATRX by promoting the trimethylation of histone H3K27 in the FADD promoter region. Here, ATRX is linked to central nervous system cancer.